ubs glp-1 sales forecast Antagonists Increase Plan Drug Spend - What's Next GLP-1 Obesity Home Delivery Injectables
Description
HR 1.19, 95% CI 0.91.58), but not for the other DPP-4 inhibitors as in the TECOS study for sitagliptin (HR 1.00, 95% CI 0.831.20) or the CARMELINA study for linagliptin (HR 0.90, 95% CI 0.741.08) (57, 62, 64, 65, 68)
10.2337/dc14-1142 80
The Ascletis platform Ascletis Pharma is a Hong Kong-listed (1672.HK) biotech focused on metabolic disease
2025;136(4):e70021
[DOI] [PubMed] [Google Scholar] 64.Garvey W.T., Batterham R.L., Bhatta M., Buscemi S., Christensen L.N., Frias J.P., et al
Reddy's Laboratories Limited for manufacturing and marketing Semaglutide Tablets in strengths of 3 mg,7 mg, and 14 mg for the treatment of Type 2 Diabetes Mellitus
